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Aims: Evolving debate suggests that handgrip strength (HGS), a measure of muscular strength, might be 
associated with the risk of type 2 diabetes (T2D); however, the evidence is conflicting. Using a systematic 
review and meta-analysis of published observational cohort studies in general populations, we aimed to 
assess the association of HGS with the future risk of T2D.  
Methods: Relevant studies were sought from inception until April 2020 in MEDLINE, Embase, Web of 
Science, and manual search of relevant articles. Transformed or extracted relative risks (RRs) with 95% 
confidence intervals (CIs) comparing the top vs bottom thirds of HGS levels were pooled using random 
effects meta-analysis.  
Results: A total of 10 unique observational cohort studies comprising of 177,826 participants and >5,167 
T2D cases were eligible. The pooled multivariable RR (95% CI) for T2D comparing the top vs bottom 
thirds of HGS levels was 0.73 (0.63-0.84). This association was consistent across several relevant 
subgroups except for evidence of effect modification by sample size (p-value for meta-regression<0.001): 
evidence of an association in smaller studies (< 250 events) 0.50 (0.40-0.63), with no significant 
association in bigger studies (≥ 250 events) 0.87 (0.73-1.05). There was no evidence of small study 
effects using formal tests such as funnel plots and Egger’s regression symmetry test. 
Conclusion: Pooled analysis of observational cohort studies suggests that HGS may be a risk indicator 
for T2D in the general population. The role of utilizing handgrip strength measurements in T2D 
prevention strategies warrants further investigation.  
Systematic review registration: PROSPERO 2020: CRD42020181434 
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Diabetes and its complications pose a major global public health threat.1 Diabetes mellitus in all forms is 
the ninth major cause of death.2 Globally, 1 in 11 adults have diabetes mellitus, of whom 90% have type 2 
diabetes (T2D).1 Older age, obesity, family history of T2D, genetic and lifestyle factors such as physical 
inactivity, smoking, unhealthy diet and excessive alcohol are major risk factors for T2D. Although, 
established risk factors explain a large proportion of T2D risk, identification of individuals at elevated 
risk of T2D still constitutes a difficult undertaking, as a significant amount of residual risk remains to be 
fully ascertained. This suggests a need to identify and investigate putative risk factors that may have both 
predictive and causal relevance for T2D and could aid in the development and implementation of newer 
therapeutic and preventive strategies. 
 
There is established evidence on the role of regular physical activity in promoting physical fitness and 
reducing the incidence of chronic disease as well as mortality risk.3,4 Physical fitness is one of the 
strongest predictors of individual future health status5 and has cardiorespiratory fitness (CRF) and 
muscular fitness as its main components;5 with muscular fitness comprised of muscular strength, 
muscular endurance and muscular power.5 The inverse and independent relationship between CRF and 
vascular disease and mortality, and its ability to predict these outcomes is well established.6-9 Handgrip 
strength, widely adopted as a proxy for muscular strength10,11 and a measure of physical fitness, has also 
emerged as a strong risk indicator for adverse health outcomes. Several prospective studies have 
demonstrated HGS to be inversely and independently associated with vascular and non-vascular disease, 
as well as mortality outcomes.12-17 High HGS reflects the ability to participate in regular muscle-
strengthening activities and also physical activity which increases or maintains CRF, which may prevent 
morbidity and mortality by having beneficial effects on resting metabolic rate, adipose tissue, blood 
glucose levels, insulin response and sensitivity, and blood pressure levels.5 Emerging data suggests that 




shown inverse associations between HGS and T2D,18-21 whereas other studies have demonstrated no 
evidence of an association.22,23 A number of these studies have also been based on cross-sectional and 
case-control designs, which do not provide evidence of temporality. A previous review attempted to 
synthesize the evidence on the association between muscular strength (handgrip strength) and T2D;24 
however, it included studies with a mix of exposures – HGS alone, muscular strength assessed in both the 
upper and lower body, as well as total body muscular strength. Given that there is evidence suggesting 
that HGS may not always be a proxy for overall muscle strength,25,26 whether a prospective relationship 
exists between HGS specifically and risk of T2D needs evaluation. Given the uncertainty in the evidence, 
our aim was to assess the nature and magnitude of the association of HGS with the risk of T2D using a 
systematic review and meta-analysis of available published observational cohort studies. 
 
2. MATERIALS AND METHODS 
2.1 Data sources and searches 
This review which was registered in the PROSPERO prospective register of systematic reviews 
(CRD42020181434) was based on a predefined protocol and conducted in accordance with PRISMA and 
MOOSE guidelines 27,28 (Tables S1-S2). We searched MEDLINE and Embase from inception to 21 April 
2020 with no restrictions placed on language. The computer-based searches used a combination of key 
words or terms relating to the exposure (“handgrip strength”, “muscular strength”) and outcome (“type 2 
diabetes”). The full search strategy is reported in Table S3. One author (SKK) screened titles and 
abstracts of retrieved citations to assess their suitability for potential inclusion, followed by acquisition of 
full texts for detailed evaluation. Full text evaluation was independently conducted by two authors (SKK 
and NMI). The reference lists of relevant studies and review articles were manually scanned for additional 






2.2 Eligibility criteria 
The protocol was pre-specified to include general population-based observational cohort (retrospective or 
prospective, case cohort, or nested case-control) studies if they had at least 1 year of follow-up and 
examined the relationship of HGS with the risk of incident T2D in adult patients. The following studies 
were excluded: (i) case-control study designs and (ii) those in individuals with pre-existing history of 
diabetes.  
 
2.3 Data extraction and quality assessment  
One author (SKK) initially extracted relevant data from eligible studies using a predesigned data 
collection form and a second author (NMI) independently checked the data with that in original articles. 
Data were extracted on (i) study design characteristics (geographical location, year of enrolment, study 
design, sample size, and follow-up); demographic characteristics (age, sex); exposure assessment; and 
outcomes (number of T2D events and the most fully-adjusted relative risks (RRs), hazard ratios (HRs), or 
odds ratios (ORs) of outcomes (and corresponding 95% confidence interval [CIs]). When there were 
multiple publications involving the same cohort, study selection was limited to a single set of most 
comprehensive results to avoid double counting of study participants in the pooled analysis. The key 
criterion used for selection was the most up-to-date comprehensive study (longest follow-up or analysis 
covering the largest number of participants). Methodological quality of studies was assessed using the 
nine-star Newcastle–Ottawa Scale (NOS),29 which uses pre-defined criteria namely: selection (population 
representativeness), comparability (adjustment for confounders), and ascertainment of outcome. Nine 
points on the NOS reflects the highest study quality.  
 
2.4 Statistical analyses 
The summary measure of association was presented as a RR with 95%CI. Hazard ratios and odds ratios 




reported HRs are constant across the follow-up period.30 To enable a consistent approach to the meta-
analysis, enhance pooling and interpretation of the results, reported study-specific risk estimates were 
transformed to comparisons involving the top versus bottom tertiles of HGS values using standard 
statistical methods, 31,32 which have been described in previous reports.33,34 For comparisons that could not 
be transformed, the extreme groups as reported (ie, maximum versus minimal value of HGS) were used 
for the analyses, described previously.4 This methodology utilised in a previous review4 is considered 
reliable as we have shown that pooled estimates from transformed and untransformed data are 
qualitatively similar.35 When the highest HGS was the referent, we converted the reported risk estimate 
into its reciprocal. Risk estimates were pooled using a random effects model to minimize the effect of 
between-study heterogeneity.36 Between study statistical heterogeneity was quantified using standard chi-
square tests and the I2 statistic.37  To determine the degree of heterogeneity, we also estimated 95% 
prediction intervals which provide a region in which about 95% of the true effects of a new study are 
expected to be found.38,39 Pre-specified study-level characteristics such as geographical location, sex, 
average age at baseline, average duration of follow-up, number of cases, and methodological quality were 
explored as sources of heterogeneity, using stratified analysis and random effects meta-regression.40 We 
also assessed the potential for small study effects such as publication bias through formal tests, namely 
Begg’s funnel plots41 and Egger’s regression symmetry test.42 All statistical analyses were performed 
using Stata version MP 16 (Stata Corp, College Station, Texas). 
 
3. RESULTS 
3.1 Study identification and selection 
The selection of eligible studies is illustrated in Figure 1. We retrieved 87 relevant articles from the 
search of the databases and manual screening of relevant articles. Following screening of titles and 
abstracts, 18 citations were eligible for full text evaluation. Following evaluation, 8 articles were excluded 




relevant (n=2); and (iv) based on a review (n=1). In aggregate, we included 10 articles representing 10 
unique observational cohort studies comprising of 177,826 general population participants (including > 
5,167 T2D events).20,23,43-50 
 
3.2 Study characteristics and quality 
Table 1 summarises baseline characteristics of the eligible studies evaluating the associations between 
HGS and T2D. Publication years ranged from 2007 to 2019 and all the studies were based on prospective 
cohort designs. The average age at baseline ranged from approximately 37.0 to 74.0 years, with a 
weighted mean (SD) of were 51.0 (4.5) years. Except for two studies which enrolled only male or female 
participants, the rest enrolled both males and females. Five studies were based in North America (Canada 
and USA); two in Europe (Switzerland and UK); one was multinational (17 countries); and one each in 
Asia (Japan) and the Pacific (Australia). Average duration of follow-up ranged from 4.0 to 19 years, with 
a weighted mean (SD) of 4.7 (2.2) years. Though there was slight variation in the degree of covariate 
adjustment, all studies adjusted for at least four conventional risk factors for T2D such as age, sex, body 
mass index (BMI), smoking status, alcohol consumption, family history of diabetes, physical activity, or 
prevalent hypertension. Overall methodological quality scores of studies ranged from 7 to 9 (Table 1 and 
Table S4). 
 
There was considerable variation in tools and methods of assessing HGS across studies; the Jamar hand-
held dynamometer appeared to be commonly used among studies (Table 2). Three studies reported HGS 
as weight normalised values.20,46,49 The majority of studies defined T2D as stated by the American 
Diabetes Association (ADA) based on a fasting plasma glucose of ≥7 mmol/l (126 mg/dl) (Table 2). 
Additional definitions included glycated haemoglobin ≥6·5% (48 mmol/mol), self-reported physician 






3.3 Handgrip strength and risk of T2D 
The pooled fully-adjusted RR (95% CI) of T2D comparing the top versus bottom third of HGS values 
was 0.73 (0.63 to 0.84) (Figure 2). The 95% prediction interval for the pooled RR was 0.48 to 1.12%, 
which is the range for the true RR for any new single study. There was substantial heterogeneity between 
the contributing studies (I2=74%, 51 to 86%; p<0.001). Little of the heterogeneity in the contributing 
studies was explained by differences in several study level characteristics other than study size (p for 
meta-regression<0.001); smaller studies (number of T2D events < 250) reported a decreased risk of T2D, 
whereas there was no evidence of an association in bigger studies (number of T2D events ≥ 250) (Figure 
3). 
Several sensitivity analyses were conducted to test the robustness of the observed association. 
Exclusion of any single study at a time from the meta-analysis did not change the direction of the 
association, yielding pooled RRs (95% CIs) which ranged from 0.69 (0.56-0.86) to 0.79 (0.70-0.88) 
(Figure S1). On exclusion of all three studies that used weight normalised HGS as an exposure, the RR 
(95% CI) of T2D comparing the top versus bottom third of HGS was 0.70 (0.52-0.93). 
 
3.4 Publication bias 
Though subgroup analysis suggested there might be evidence of selective reporting, a funnel plot of the 
10 studies reporting on the associations between HGS and the risk of T2D showed no evidence of 
asymmetry (Figure S2), which was consistent with Egger’s regression symmetry test (p=0.21).  
 
4. DISCUSSION 
Though abundant evidence suggests an independent association between HGS and risk of vascular events, 
the relationship between HGS and T2D has been uncertain. In this meta-analysis of 10 population-based 




association remained robust and significant in several sensitivity analyses. Subgroup analyses using 
clinically relevant study-level characteristics suggested that the association might be modified by the 
sample size, i.e., there was a tendency for smaller studies to report positive findings (small study effects); 
however, our formal tests for small study effects showed no evidence of this bias.  In a previous effort to 
aggregate existing data on the relation between HGS and T2D, Tarp and colleagues pooled 13 studies that 
evaluated the association between CRF, muscular strength and the risk of T2D and demonstrated that a 1 
SD higher muscular strength was associated with a 13% lower risk of T2D. 24 Whereas they included 
studies with different measures of HGS which did not enhance consistency, our evaluation specifically 
evaluated HGS as an exposure.    
 
Potential mechanisms for decreased risk of T2D in individuals with high levels of HGS have been 
postulated. The protective effect of higher HGS on vascular disease may be mediated by reduction in 
incidence of weight gain, abdominal adiposity, insulin resistance, and inflammation.5 Hence, given that 
CVD and diabetes share common risk factors such as BMI, physical activity, smoking, and inflammatory 
markers such as C-reactive protein, similar pathways may underlie the relationship between HGS and 
T2D. Resistance training, which is an effective way of increasing HGS, is able to increase muscle mass 
and strength, thus reducing visceral fat deposition and improving insulin sensitivity and glycaemic 
control.51 Handgrip strength is an indicator of frailty,11 which is often associated with fatigue, reduced 
muscle mass, and high susceptibility to chronic diseases such as CVD and T2D. These observational 
findings could also be attributed to reverse causality i.e., diabetes could be associated with lower HGS. 
Indeed, in a bi-directional Mendelian randomization study to assess the effect of markers of muscle mass 
and strength on diabetes and glycaemic traits, Yeung and colleagues demonstrated that increased grip 
strength could be related to lower diabetes risk and conversely showed diabetes to be associated with 
lower grip strength.52 Diabetes may directly contribute to muscle loss, frailty or functional disability 




skeletal muscle, mitochondrial function, and bio-energetic capacity; comorbidities such as CVD and 
obesity; and mechanisms linked to decreased cardiopulmonary reserve and restricted physical 
movement.53-55 
 
The association between elevated HGS and decreased T2D risk has clinical implications. Assessment of 
HGS may represent an important approach for T2D prevention, for instance in the areas of screening of 
individuals at risk of T2D, recommending lifestyle modification, as well as further diabetes management 
strategies. We have recently shown that information on HGS augments CVD mortality risk prediction 
beyond that of traditional risk factors and that it may be potentially suitable for population-level risk 
assessment.16 Handgrip strength may be a potential risk assessment tool in general or specialized clinical 
settings to identify patients at high risk for worse outcomes including T2D, but a formal risk prediction 
analyses is warranted. Assessment of HGS is quick and low-cost, hence studies are needed to assess its 
suitability in risk assessment. Furthermore, though there is considerable evidence that physical activity 
can prevent or delay T2D,56,57 the use of interventions which build muscle strength such as resistance 
training, could be evaluated as potential preventive strategies for T2D. 
 
Several strengths of this review deserve consideration. A comprehensive search of the major databases 
was conducted to identify all published observational cohort studies conducted on the topic, hence there 
was enhanced power to reliably assess the nature and magnitude of the prospective association between 
HGS and T2D risk. Reported risk estimates were transformed to consistent comparisons using standard 
and well-established reliable methods and this enhanced the pooling process for easy interpretation. We 
quantified and explored for sources of heterogeneity using stratification by several study level 
characteristics and estimating prediction intervals. Some important limitations included the inability to 
transform some of the risk estimates to extreme tertiles, hence comparisons could only be made between 




pooled results from untransformed data of extreme categories are not very different from results based on 
transformed data.35 There was variation in HGS assessment methods across studies, hence the pooled 
estimate may be biased. In a comprehensive review of the measurement of grip strength in clinical and 
epidemiological, Roberts and colleagues reported considerable variation in methods of assessing grip 
strength hence making comparison between studies difficult.58 The authors called for the use of a 
standardised approach by studies. The Jamar hand dynamometer is the most widely used tool and testing 
procedures should follow the American Society of Hand Therapists (ASHT) recommendations59 or the 
Southampton protocol.58 Definition of T2D outcomes did not vary much across studies, given that 
majority of studies employed ADA diagnostic criteria. Handgrip strength values were based on baseline 
assessments, hence the potential for regression dilution bias and hence possibly underestimating the 
associations. Finally, there was substantial heterogeneity between contributing studies and the estimated 
95% prediction intervals of the pooled estimate for the association between HGS and T2D risk contained 
values below and above 1, and so although on average there was evidence of an association, this may not 
always be the case in other studies. Heterogeneity was partly explained by the study size; there could be 
other sources of variation such as participants, HGS assessment, outcome ascertainment, and in the 
results, which could not be explored because of inability to access individual level data. In addition, the 
presence of substantial heterogeneity makes pooling of data somewhat controversial, but we conducted 
subgroup analyses and made great efforts to identify the possible sources of heterogeneity. In light of 
these limitations, the findings should be interpreted with caution. To address the issues with variability of 
HGS assessments, consistent adjustment for confounding, exploration of dose-response relationships and 









Pooled analysis of observational cohort studies suggests that HGS may be a risk indicator for T2D in the 
general population. The role of utilizing HGS measurements as an easily available clinical measure in the 
prevention of T2D warrants further investigation.  
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FIGURE 1 Study selection process 
87 Potentially relevant citations identified
From MEDLINE, Embase, Web of Science 
and reference lists
69 excluded on the basis of title 
and/ or abstract
8 Articles excluded due to:
3 Exposure not relevant
2 Study design not relevant
2 Population not relevant
1 Review
10 Articles included, based on 10 
unique observational cohort studies




































FIGURE 2 Association between handgrip strength and risk of T2D in prospective cohort studies 
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RR (95% CI) Top vs bottom third of HGS
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The summary estimates presented were calculated using random effects models; relative risks are 
reported comparing extreme tertiles of handgrip strength; size of data markers is proportional to the 
inverse of the variance of the relative ratio; CI, confidence interval (bars); HGS, handgrip strength; NR, 
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The summary estimates presented were calculated using random effects models; CI, confidence interval 





Table 1. Baseline characteristics of included studies (2007-2019) 
Author, year of 
publication 














Confounders adjusted for 
Katzmarzyk, 2007 Canadian PALS Canada 1988 37.2 45.9 15.5 Absolute 1,543 78 Age, sex, smoking status, alcohol consumption and 
parental history of DM 
Wander, 2011 Japanese-American 
Community Diabetes 
Study 
USA  1983-1991 51.9 53 10.0 Absolute  394 73 Age, sex, family history, and BMI 
Leong, 2015 PURE 17 
countries 
2003-2010 50.0 42 4.0 Absolute  139,691 2,939 Age; sex; education level; employment status; physical 
activity level; tobacco and alcohol use; daily dietary energy 
intake; proportion of caloric intake from protein; self-
reported hypertension, DM, HF, CAD, and COPD; and self-
reported prior stroke or cancer; BMI and WHR 
Cuthbertson, 2016 ELSA UK 2004-2005 63.0 45 6.0 Absolute  5,953 216 Age, sex, physical activity, smoking, alcohol, depressive 
symptoms and prevalent CVD 
Li, 2016 MAILES Australia 2002-2006; 
2007-2010 
54.1 100 5.0 Absolute  1,632 146 Age, income, cohort, WC, FPG, physical activity, 
hypertension, TG and family history of DM, and whole-
body lean mass 
Larsen, 2016 Health ABC USA 1997-1998 74.0 48 11.3 Absolute  2,166 265 Age, race, clinical site, physical activity, smoking, lipids, 
hypertension, BMI, visceral fat, and total body fat 
Marques-Vidal, 
2017 
CoLaus Switzerland 2003-2006 60.2   10.7 Absolute  2,318 321 Age, maternal and paternal diabetes, height, WC, alcohol 
consumption, hypertension, HR, glucose, TG, HDL-C and 
uric acid 
McGrath, 2017 HEPESE USA 1993-1994 73.3 42.1 19.0 Normalised*  1,903  NR Education level, employment status, marital status, IADL 
disability, interview language, and obesity 
Karvonen-
Gutierrez, 2018 
Michigan SWAN USA 1996 46.4 0 16.0 Normalised * 424 157 Age, race/ethnicity, difficulty paying for basics, smoking 
status, and WHR 
Momma, 2019 Niigata Wellness 
Study 
Japan 2001-2002 50.0 69.5 5.0 Normalised * 21,802 972 Age, sex, smoking status, drinking status, breakfast 
skipping, hypertension, dyslipidemia, and BMI 
*, are weight normalised values 
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein 
cholesterol; HF, heart failure; HGS, handgrip strength; HR, heart rate; IADL, instrumental activities of daily living; NR, not reported; TG, triglyceride; WC, waist circumference; WHR, waist-to-hip ratio 
Study Abbreviations: ABC, Health, Aging and Body Composition; ELSA, English Longitudinal Study of Ageing; HEPESE, Hispanic Established Population for the Epidemiological Study of the Elderly; MAILES, Men 







Table 2. Handgrip strength assessment and definition of incident T2D outcomes (2007-2019) 
 
Author, year of publication HGS tool; assessment method Definition of T2D 
Katzmarzyk, 2007 Stoelting adjustable dynamometer; the maximum grip 
strengths of three trials for each hand were summed to 
provide a single measure of grip strength 
Self-reported physician diagnosis 
Wander, 2011 Harpenden R dynamometer (British Indicators Ltd, St 
Albans, England); measured three times on the dominant 
hand (reset to 0 each time); the value entered was the 
average of the two highest values 
FPG ≥ 126 mg/dl and/or 2-hr glucose ≥ 200 mg/dl or 
use of diabetes medication. 
Leong, 2015 Jamar dynamometer; three measurements were made from 
the participant’s non-dominant hand. During the course of 
the study, the protocol was amended so that three 
measurements were made from both hands of each 
participant. We used only the maximum values obtained 
from each hand 
NR 
Cuthbertson, 2016 NR; assessed in the dominant hand and used the average 
of three measurements 
Self-reported physician diagnosis based on a FPG ≥7.0 
mmol/l 
Li, 2016 Jamar analog ((Lafayette Instrument Company, Lafayette, 
Indiana, USA) or Smedley ((Stoelting Corporation, Wood 
Dale, Illinois, USA) analog dynamometer; mean of three 
measurements used 
Previous doctor diagnosis, diabetes medication use, 
FPG ≥7·0 mmol/L (≥126 mg/dl), or HbA1c ≥6·5% (48 
mmol/mol). 
Larsen, 2016 Isometric dynamometer (Jaymar; JLW Instruments, 
Chicago, IL); Two trials were performed for each hand; 
the mean of all four readings was used as the grip strength 
measure 
FPG ≥126 mg/dL, and/or reporting a physician’s 
diagnosis of diabetes and/or use of hypoglycaemic 
medication at the follow-up examination 
Marques-Vidal, 2017 Baseline® Hydraulic Hand Dynamometer (Fabrication 
Enterprises Inc, Elmsford, NY, USA); used American 
Society of Hand Therapists’s guidelines; three 
measurements were performed consecutively with the 
right hand and maximum value used 
FPG ≥7.0 mmol/l; HbA1c levels (≥6.5% or 48 
mmol/mol). 
McGrath, 2017 Hand-held dynamometer (Jamar Hydraulic Dynamometer; 
J.A. Corp); While seated, participants performed the test 
with their dominant hand, exhaling while squeezing; wo 
trials were performed, and the higher of the two 
measurements divided by body weight was used 
Self-reported physician diagnosis 
Karvonen-Gutierrez, 2018 Baseline® hydraulic hand dynamometer; measured 
separately three times on both hands at each study visit 
while the participant was seated with her elbow bent at a 
90° angle; maximum grip strength used value used and 
divided by body weight 
(1) Self-reported doctor’s diagnosis of diabetes; (2) 
self-reported use of anti-diabetic medications (oral 
medications or insulin) or (3) FPG ≥126 mg/dl 
orHbA1c ≥6.5%. 
Momma, 2019 Grip strength dynamometer (T.K.K. 5401; Takei 
Scientific Instruments Co., Ltd, Niigata, Japan); grip 
strength was measured once for each hand alternately with 
individuals in standing position; the highest value was 
used and divided by body weight 
FPG ≥126 mg=dL (7.0 mmol=L), HbA1c ≥48 
mmol=mol (6.5%), or a self-reported history of 
previously diagnosed diabetes or current medication for 
diabetes 
 









Table  S1 PRISMA checklist 
Table S2 MOOSE checklist 
Table S3 Literature search strategy 
Table S4 Methodological quality of studies using NOS criteria 
Figure S1 Relative risks on exclusion of a study one at a time 









No Checklist item 
Reported on page 
No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility 
criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and 
implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated 
Table S2 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions 
and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 
Results and Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Results, Table 1 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
Results, Figure 2  
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figure 2 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Table 1, Figure 3 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see 
item 16) 





24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete 
retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of 




Table S2. MOOSE checklist  
 
Handgrip strength – a risk indicator for type 2 diabetes: systematic review and meta-
analysis of observational cohort studies 
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Evidence on the association between handgrip strength and type 2 diabetes 
(T2D) is inconsistent 
 Hypothesis statement Handgrip strength is associated with T2D 
 Description of study outcomes Type 2 diabetes 
 Type of exposure  Handgrip strength 
 Type of study designs used Prospective cohort studies 
 Study population Adult general populations with assessment of handgrip strength at study 
entry 
Reporting of search strategy should include  
 Qualifications of searchers Setor K. Kunutsor, PhD; Nzechukwu Isiozor, MD 
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 21 April 2020  
The detailed search strategy can be found in Appendix 3 
 Databases and registries searched MEDLINE, Embase, Web of Science 
 Search software used, name and version, 
including special features 
OvidSP was used to search Embase and MEDLINE 
EndNote X9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with authors None 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Heterogeneity of the studies was quantified with I2 statistic that provides the 
relative amount of variance of the summary effect due to the between-study 
heterogeneity and explored using meta-regression and stratified analyses 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, meta-
regression and assessment of publication bias are detailed in the methods. We 
performed random effects meta-analysis with Stata 15. 
 Provision of appropriate tables and 
graphics 
Table 1; Figures 1-3; Figure S1 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figure 2 
 Table giving descriptive information for 
each study included 
Table 1 
 Results of sensitivity testing 
 
Sensitivity analysis was conducted to assess the influence of some large 
studies and low-quality studies on the pooled estimate.  
 
 
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, I2 
values and results of sensitivity analyses 
Reporting of discussion should include  
 Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of the association due 
to most common biases in observational studies.  The systematic review is 
limited in scope, as it involves published data. Individual participant data is 
needed. Limitations have been discussed. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend individual participant data meta-analysis 




Table S3. Literature search strategy 
Relevant studies, published from inception to 21 April 2020 (date last searched), were identified through electronic searches using MEDLINE and 
Embase databases. Electronic searches were supplemented by scanning reference lists of articles identified for all relevant studies (including review 
articles), by hand searching of relevant journals and cited reference search in Web of Science. 
Database: Ovid MEDLINE(R) <1946 to present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     handgrip strength.mp. (2703) 
2     grip strength.mp. (10948) 
3     exp Muscle Strength/ (33011) 
4     muscular strength.mp. (3294) 
5     exp Diabetes Mellitus, Type 2/ (130550) 
6     cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or cohort.ti,ab. or 
longitudinal.ti,ab. or prospective.ti,ab. or retrospective.ti,ab. (2565855) 
7     1 or 2 or 3 or 4 (42248) 
8     5 and 6 and 7 (58) 
9     limit 8 to humans (58) 
*************************** 
 




Table S4. Methodological quality of studies using NOS criteria 
 
Author, year of publication Selection Comparability Outcome Total score 
Katzmarzyk, 2007 4 2 2 8 
Wander, 2011 3 1 3 7 
Leong, 2015 4 2 3 9 
Cuthbertson, 2016 4 2 2 8 
Li, 2016 4 2 3 9 
Larsen, 2016 3 2 3 8 
Marques-Vidal, 2017 3 2 2 7 
McGrath, 2017 3 1 3 7 
Karvonen-Gutierrez, 2018 3 2 2 7 




Figure S1. Relative risks on exclusion of a study one at a time 
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